Allakos Inc

Allakos Inc. is a clinical-stage biotechnology company based in California that develops monoclonal antibody therapies aimed at diseases driven by eosinophils and mast cells; its lead program is an anti–Siglec‑8 antibody (known as AK002 or lirentelimab) designed to deplete eosinophils and inhibit mast cell activity for indications such as eosinophilic gastritis/gastroenteritis and certain allergic and inflammatory conditions. The company advances its pipeline through clinical trials, seeks regulatory approvals for late-stage candidates, and pursues commercial and partnership strategies typical of small specialty biopharma firms.